LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Listă Acțiuni・Sana Biotechnology Inc

Sana Biotechnology Inc

Închisă

SectorSănătate

3.21 -3.02

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.14

Maxim

3.37

Indicatori cheie
By Trading Economics
Venit	12M -47M
EPS	-0.171
Angajați	142
EBITDA	23M -35M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+208.18% upside

Dividende
By Dow Jones
Următoarele câștiguri	7 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-107M 854M
Deschiderea anterioară	6.23
Închiderea anterioară	3.21

Sentimentul știrilor

By Acuity

25%

75%

47 / 344 Clasament în Healthcare

Sana Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 iun. 2026, 23:38 UTC

Achiziții, Fuziuni, Preluări

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 iun. 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 iun. 2026, 22:08 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 iun. 2026, 22:01 UTC

Achiziții, Fuziuni, Preluări

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 iun. 2026, 21:55 UTC

Achiziții, Fuziuni, Preluări

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 iun. 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 iun. 2026, 21:22 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 iun. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 iun. 2026, 20:46 UTC

Achiziții, Fuziuni, Preluări

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 iun. 2026, 20:22 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares $11 Special Div

1 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 iun. 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 iun. 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 iun. 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 iun. 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 iun. 2026, 18:54 UTC

Achiziții, Fuziuni, Preluări

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 iun. 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 iun. 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 iun. 2026, 18:00 UTC

Achiziții, Fuziuni, Preluări

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 iun. 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 iun. 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 iun. 2026, 17:10 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparație

Modificare preț

Sana Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

208.18% sus

Prognoză pe 12 luni

Medie 10.17 USD 208.18%

Maxim 16 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSana Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Sana Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

47 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.